Abiomed statement to Axios on Michael Minogue’s 2019 compensation
“The vast majority of the 2019 compensation originates from stock options and performance shares
awarded over the previous 10 years, during which Abiomed’s market cap increased 50x from $400
million to $20 billion. The compensation includes a large number of 10-year stock options that had to be
exercised before they expired. The options grew significantly since being granted, due to Abiomed’s stock
being one of the top 3 performing NASDAQ stocks of the decade. It is worth noting that Mr. Minogue still
owns the exercised and vested shares, is one of the larger shareholders in the company, and is currently
not taking a salary during the coronavirus pandemic.”